** Shares of Integral Diagnostics IDX.AX rise 4.7% to A$2.25
** Citi upgrades healthcare facilities provider to 'Buy' from 'Neutral,' keeps PT unchanged at A$2.70
** Brokerage forecasts higher revenue and margins for IDX in FY26, buoyed by partial MRI de-regulation, potential lung cancer screening contract, and benefits from Capitol Health merger
** Stock rose 5.1% earlier in the session
** 13 analysts rate the stock "buy" or higher and 1 "hold"; their mean PT is A$3.13 – LSEG
** Including session's gains, stock trims YTD decline to 22.3%
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.